Edition:
United Kingdom

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

4.45USD
22 May 2018
Change (% chg)

$-0.08 (-1.77%)
Prev Close
$4.53
Open
$4.70
Day's High
$4.72
Day's Low
$4.41
Volume
84,865
Avg. Vol
65,730
52-wk High
$14.09
52-wk Low
$4.39

Chart for

About

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel... (more)

Overall

Beta: --
Market Cap(Mil.): $218.87
Shares Outstanding(Mil.): 40.31
Dividend: --
Yield (%): --

Financials

  NBRV.OQ Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -2.27 -- --
ROI: -94.22 -7.75 12.60
ROE: -94.83 -10.55 14.49

Nabriva shares tumble as safety worries plague pneumonia drug

Nabriva Therapeutics Plc's antibiotic drug to treat a common form of pneumonia met the main goal of a key clinical trial, but concerns over its side effects sent the drug developer's shares down 13 percent on Monday.

21 May 2018

UPDATE 3-Nabriva shares tumble as safety worries plague pneumonia drug

* Co to seek approval for drug in Q4 2018 (Adds analyst quote, updates stock price)

21 May 2018

Nabriva's pneumonia drug succeeds in late-stage study

May 21 Nabriva Therapeutics Plc said on Monday its drug to treat adults suffering from a type of pneumonia met the main goal of a late-stage study.

21 May 2018

BRIEF-Nabriva Therapeutics Reports Q1 Loss Per Share $0.36

* NABRIVA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

08 May 2018

BRIEF-Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement

* NABRIVA THERAPEUTICS AND ROIVANT SCIENCES ENTER INTO LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LEFAMULIN IN GREATER CHINA

27 Mar 2018

BRIEF-Nabriva Appoints Jennifer Schranz As Chief Medical Officer

* NABRIVA THERAPEUTICS APPOINTS JENNIFER SCHRANZ, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

21 Mar 2018

BRIEF-Nabriva Therapeutics PLC Files For Mixed Shelf Of Upto $225 Million - SEC Filing

* NABRIVA THERAPEUTICS PLC FILES FOR MIXED SHELF OF UPTO $225 MILLION - SEC FILING Source text (http://bit.ly/2HEW5CR) Further company coverage: (Reuters.Brief@thomsonreuters.com)

16 Mar 2018

BRIEF-Nabriva Therapeutics ‍had $86.9 Mln In Cash, Cash Equivalents as Of Dec 31

* NABRIVA THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

16 Mar 2018

Earnings vs. Estimates